Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Denmark / NCT07687589
Enrolling by invitation Not applicable

The Antiemetic Effects of Increased Splanchnic Perfusion, Induced by the Gut Hormone GIP, in Healthy Individuals

NCT07687589 · tracked via the Priya Life Science Denmark tracker
Sponsor
University of Copenhagen
Phase
Not applicable
Started
2026-05-19
Last updated
2026-07-07

Condition(s) studied

Emesis

Investigational drug(s) / intervention(s)

Glucose-dependent Insulinotropic Polypeptide (GIP)GLP-1 (7-36) amideApomorphine Injectable SolutionSaline (0.9% NaCl)

Glucose-dependent Insulinotropic Polypeptide (GIP): GIP - gut hormone

GLP-1 (7-36) amide: gut hormone - GLP-1(7-36)NH2

Apomorphine Injectable Solution: used as a tool to induce nausea

Saline (0.9% NaCl): Placebo

Study summary

This study investigates whether the gut hormone glucose-dependent insulinotropic polypeptide (GIP) can reduce feelings of nausea. GIP is naturally released after meals and is administered intravenously to healthy participants during the experiment. Nausea is induced using either glucagon-like peptide 1 (GLP-1), another gut hormone, or apomorphine, a medication known to trigger nausea. By combining these substances, the study aims to determine whether GIP can alleviate nausea. The findings may improve understanding of interactions between the gut and the brain.

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Men or women, age of 18-60 years * BMI between 19-27 kg/m2 (both included) * informed consent Exclusion Criteria: * Current or past treatment with GLP-1 or GIP/GLP-1 receptor-targeting compounds within the last six months * Gastrointestinal disorders that the investigator evaluates could interfere with induction of nausea (e.g. gastroparesis, functional dyspepsia and GI surgery) * Neurological disorders affecting nausea (e.g. severe migraines and neuropathy) * Any known eating disorders (e.g. anorexia nervosa and bulimia) * Pregnancy or breastfeeding * Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) (\> 2 times normal values) or present hepatobiliary disease * Kidney disease (estimated glomerular filtration rate (eGFR)\<90 ml/min/1.73 m2) at screening * Severe arteriosclerotic heart disease or heart failure (NYHA class II-IV) * Glycated hemoglobin (HbA1c) ³ 48 mmol/mol and/or diagnosed type 1 or type 2 diabetes * Any condition that the investigator evaluates would interfere with study participation

Primary outcome measure(s)

  • Change in GLP-1 induced nausea intensity — From enrollment to the end of treatment at up to 12 weeks.
    The primary endpoint is the change in GLP-1-induced nausea intensity, measured by a 0-100 mm visual analogue scale (VAS), between study visits, with and without GIP infusion.

Trial sites (1)

FacilityCityRegionStatus
Center for Clinical Metabolic Research, Herlev-Gentofte Hospital Hellerup Denmark

More University of Copenhagen trials in Denmark

Cancer-associated Muscle Mass - Molecular Factors and Exercise Mechanisms Recruiting
Ayurvedic Diet in Myxedema Recruiting
Does Paracetamol Influence the Release of Gut Hormones, Glucose Absorption and Glycemia? Recruiting
GastroFlow: Investigation of the Gastrointestinal Blood Flow in Patients With Postprandial Hypotension Enrolling by invitation
The Effect of Fasting on Peak Fat Oxidation, Mitochondrial Coupling and Extracellular Matrix Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07687589 on ClinicalTrials.gov ↗ ← All trials in Denmark